XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX)

Key Points

• XTX Topco Ltd reduced its stake in REGENXBIO Inc. by 66.7% during the 1st quarter, now holding approximately 0.07% of the company valued at $257,000.
• Analysts have varied opinions on REGENXBIO's stock, with Goldman Sachs lowering its price target to $12.00 while Chardan Capital maintains a "buy" rating with a target of $52.00.
• REGENXBIO reported a significant loss, missing earnings estimates by $0.25, with a revenue of $21.36 million compared to expectations of $40.87 million.

XTX Topco Ltd lowered its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 66.7% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 35,953 shares of the biotechnology company's stock after selling 72,167 shares during the quarter. XTX Topco Ltd owned approximately 0.07% of REGENXBIO worth $257,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Janney Montgomery Scott LLC purchased a new position in shares of REGENXBIO in the 1st quarter valued at approximately $484,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of REGENXBIO in the 1st quarter valued at approximately $123,000. Price T Rowe Associates Inc. MD lifted its stake in shares of REGENXBIO by 9.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock valued at $185,000 after purchasing an additional 1,982 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of REGENXBIO by 370.1% in the 4th quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock valued at $743,000 after purchasing an additional 75,652 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of REGENXBIO by 34.0% in the 4th quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company's stock valued at $374,000 after purchasing an additional 12,285 shares during the period. Hedge funds and other institutional investors own 88.08% of the company's stock.

Analysts Set New Price Targets

RGNX has been the subject of a number of recent research reports. The Goldman Sachs Group lowered their price objective on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Barclays lowered their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research note on Friday. Wall Street Zen cut REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday. Chardan Capital reiterated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Friday. Finally, Royal Bank Of Canada lowered their price objective on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $28.38.

REGENXBIO Trading Down 5.0%

REGENXBIO stock opened at $7.46 on Tuesday. The firm has a market cap of $376.80 million, a price-to-earnings ratio of -2.17 and a beta of 1.11. The stock has a fifty day simple moving average of $8.73 and a two-hundred day simple moving average of $8.03. REGENXBIO Inc. has a 12 month low of $5.03 and a 12 month high of $13.48.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). The business had revenue of $21.36 million during the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. On average, equities research analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.